Protocol Ledger

NCT03840902 · Phase II · TERMINATED

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

Interventional Phase II clinical trial protocol NCT03840902 sponsored by EMD Serono / Merck KGaA in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-04-16 Enrollment: 153 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03840902
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)153 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03840902
Protocol FieldVerified Registry Value
NCT IdentifierNCT03840902
Consolidated Lead SponsorEMD Serono / Merck KGaA
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment153 participants (ACTUAL)
Registered Start Date2019-04-16
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI